uniQure Archives - PharmaDeviceNews

Can uniQure turn the FDA’s AMT-130 reversal into a Huntington’s disease approval?

By Pallavi Madhiraju on June 20, 2026 Pharma & Biotech

The Food and Drug Administration will accept uniQure’s three-year AMT-130 data as the primary basis for an accelerated approval filing, but external controls, irreversible brain delivery and confirmatory evidence remain decisive risks.

Can uniQure’s AMT-260 gene therapy become an alternative to epilepsy surgery?

By Pallavi Madhiraju on June 20, 2026 Pharma & Biotech

Explore whether uniQure’s AMT-260 gene therapy can rival epilepsy surgery after early seizure reductions in a small first-in-human cohort.

Why AMT-260’s early epilepsy data could shape the next test for brain-delivered gene therapy

By Soujanya Ravi on June 19, 2026 Pharma & Biotech

$Representative image of a neurology consultation with brain scan review, reflecting coverage of uniQure’s AMT-260 gene therapy data and its potential role in refractory mesial temporal lobe epilepsy treatment.$

Find out how uniQure’s AMT-260 early epilepsy data could shape the next test for brain-delivered gene therapy.

FDA accepts uniQure’s AMT-130 filing strategy after months of regulatory uncertainty

By Pallavi Madhiraju on June 18, 2026 Pharma & Biotech

Explore why the FDA reopened uniQure’s AMT-130 approval path and what evidence, surgical and confirmatory trial risks remain before review.